Independent Reference Labs
Lab Solutions for Independent Reference Labs
Compliant pathways that help your lab keep its UTI PCR testing program going, expand what you offer, and continue serving the physicians who rely on you.
Built for Independent Reference Labs
Independent reference labs are under constant pressure to keep pace with what referring physicians ask for, including new tests, faster turnaround, and broader capabilities, while navigating the regulatory, reimbursement, and compliance realities of running a lab. Reimbursement pressure on UTI PCR testing has added another layer, leaving many labs weighing whether to scale back a program their physicians rely on.
Doc Lab works with each lab individually to build a compliant structure that fits its situation, whether that means keeping testing in-house, sending out what you don't or can't perform, or a combination. Any arrangement can serve as a long-term solution or as a bridge to the full Doc Lab program.
Whether you set up or send out, Doc Lab® brings the rigorous science, proven expertise, and hands-on support to be the right partner for your lab and the physicians you serve.
Every Lab Is Different
No two labs share the same clients, payers, jurisdiction, or goals, so there's no standard package. Doc Lab starts with a conversation to understand where your lab is today, then works with you to build a compliant path that keeps your community of clients served and your lab thriving.
Beyond UTI PCR
Doc Lab can also support additional in-house testing programs, including TrueUA™, Vaginitis PCR, STI PCR, Quad RPP, and blood hormone testing. For testing your lab needs to outsource, SoftCell Labs, a Doc Lab-owned lab, accepts samples for PGx, FISH, MiCheck® Prostate, and urine cultures, as well as the molecular tests. Together, we'll customize an approach that brings your lab the most economic stability while continuing to serve your clients.
Why Independent Reference Labs Choose Doc Lab
-
Evidence Payers Ask For
Doc Lab's UTI PCR testing is validated by a completed multicenter, investigator-blinded randomized clinical trial (ClinicalTrials.gov NCT06996301), giving labs a defensible clinical-utility story for payers and auditors.
-
A Defensible Billing Strategy
UTI Max has its own AMA-issued Proprietary Laboratory Analyses (PLA) code, supporting a single, defensible billing approach where many labs are getting stuck.
-
Proprietary Reagents, Real Support
Reagents and assays developed to Doc Lab's own specifications through years of R&D, with quality control and technical support from the people who understand the chemistry.
Doc Lab: where rigorous science meets real partnership.
Let's talk
Ready to Protect and Grow Your Lab's Testing?
Tell us about your lab, your jurisdiction, and the physicians you serve. We'll listen first, then work with you to find the right path forward for your lab and the clients who depend on it.